GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (STU:25K) » Definitions » Net Intangibles Purchase And Sale

Karyopharm Therapeutics (STU:25K) Net Intangibles Purchase And Sale : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Karyopharm Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was €0.0 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Karyopharm Therapeutics Net Intangibles Purchase And Sale Historical Data

The historical data trend for Karyopharm Therapeutics's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Net Intangibles Purchase And Sale Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -4.87 - -

Karyopharm Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Karyopharm Therapeutics Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (STU:25K) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (STU:25K) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
ABEO BDTX SGMO GMDA OCGN MNOV NYMXF PRQR ALDX RLMD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KPTI:USA
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Website
https://www.karyopharm.com
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (STU:25K) Headlines

No Headlines